News Scancell points to 'strong' melanoma vaccine data Scancell has the results it was hoping for with its melanoma immunotherapy iSCIB1+ and is accelerating plans for a pivotal trial.
News AstraZeneca reveals $50bn investment in US facilities Trump's pharma tariffs haven't appeared yet, but AstraZeneca has joined several of its peers with big investments in US manufacturing and R&D.
News Sarepta backs down and pauses Elevidys shipments The FDA seems to have won its staring contest with Sarepta over shipments of Elevidys, as the company blinks and agrees to a pause from today.
News Sanofi to buy UK vaccines developer Vicebio for $1.6bn Sanofi has agreed to buy UK start-up Vicebio, set up to produce improved, more potent shots that are simpler to manufacture, for $1.15bn upfront.
News FDA names a new CDER director, choosing a biotech vet The FDA has rounded out its senior leadership by naming biopharma industry executive George Tidmarsh to the role of CDER director.
News First-in-class hay fever immunotherapy backed for NHS use A once-daily tablet that can help people suffering from hay fever caused by tree pollen, Alk-Abelló's Itulazax, has been recommended for NHS use.
Digital Post-ASCO 25: Pamela Tenaerts on CGTs and digital-first long... In a post-ASCO 2025 conversation, pharmaphorum web editor Nicole Raleigh spoke with Dr Pamela Tenaerts, chief medical officer at Medable.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face